Faculty, Staff and Student Publications
Language
English
Publication Date
6-14-2023
Journal
Science Translational Medicine
DOI
10.1126/scitranslmed.abq4006
PMID
37315113
PMCID
PMC10759507
PubMedCentral® Posted Date
June 2023
PubMedCentral® Full Text Version
Post-print
Abstract
Immune checkpoint inhibitors (ICIs) target advanced malignancies with high efficacy but also predispose patients to immune-related adverse events like immune-mediated colitis (IMC). Given the association between gut bacteria with response to ICI therapy and subsequent IMC, fecal microbiota transplantation (FMT) represents a feasible way to manipulate microbial composition in patients, with a potential benefit for IMC. Here, we present a large case series of 12 patients with refractory IMC who underwent FMT from healthy donors as salvage therapy. All 12 patients had grade 3 or 4 ICI-related diarrhea or colitis that failed to respond to standard first-line (corticosteroids) and second-line immunosuppression (infliximab or vedolizumab). Ten patients (83%) achieved symptom improvement after FMT, and three patients (25%) required repeat FMT, two of whom had no subsequent response. At the end of the study, 92% achieved IMC clinical remission. 16
Keywords
Immune Checkpoint Inhibitors, Colitis, Fecal Microbiota Transplantation, RNA, Ribosomal, 16S, Feces, Humans, Male, Female, Middle Aged, Aged
Recommended Citation
Halsey, Taylor M; Thomas, Anusha S; Hayase, Tomo; et al., "Microbiome Alteration Via Fecal Microbiota Transplantation Is Effective For Refractory Immune Checkpoint inhibitor-induced Colitis" (2023). Faculty, Staff and Student Publications. 372.
https://digitalcommons.library.tmc.edu/uthsph_docs/372